Liver Testing Through a New Investigative Tool
Function Matters
HepQuant: A minimally invasive assessment of chronic liver disease
New Investigative Tools to Evaluate the Liver
assessment of chronic liver disease
Novel technology for minimally invasive
Liver Function Tests: Breaking Through Conventional Thinking About Liver Health Testing
HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.
Upcoming Events
Dr. Greg Everson Will Be Presenting at NASH Summit
Dr. Greg Everson, inventor of the HepQuant tests and founder of HepQuant, LLC, will be presenting at the NASH Summit in Boston, on Tuesday, April 24th at 12 p.m.
Come listen to Dr. Everson speak about “The HepQuant Function Tests for Assessing Liver Disease.” His presentation will be part of the Clinical Stream track.
HepQuant will also be presenting a poster at Nash Summit 2018: “Identifying Potential Subjects for NASH Clinical Trials Using the HepQuant Quantitative Liver Tests”
HepQuant will attend the 3rd International Workshop on NASH Biomarkers, to be held in Washington DC, USA on 18-19 May 2018.
HepQuant will be attending the AASLD Drug Induced Liver Injury Annual Conference in June.
Recently Presented
HepQuant was discussed by at the October 2017 AASLD Meeting during an NAFLD Debrief. For AASLD member access to the presentation, please click here.
Here is a link to our 2017 AASLD presentation on “Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test.”
A recent presentation at the American Society of Clinical Oncology (ASCO) meeting highlighted a new potential use of HepQuant SHUNT – monitoring impact of cancer treatment on global liver function. (Link to abstract and poster)
LATEST NEWS
- Richard Whitcomb Named Chief Operating Officer
- HepQuant and CTI Clinical Trial and Consulting Services Announce First Patient Enrolled in Liver Disease Diagnostic Trial
- HepQuant Presented Poster as Finalist at RESI San Francisco Innovation Challenge
- HepQuant Presented at the 10th Annual Biotech Showcase
- HepQuant held its 2017 Scientific Advisory Board Meeting in Washington D.C.
- HepQuant to Sponsor its First Clinical Study
CONTACT US
These links are for informational purposes only and do not imply that HepQuant has any formal relationships with the organizations, nor do the organizations endorse HepQuant or its liver function tests.